Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas : Implications for Future Targeted Therapies - 28/06/12

Doi : 10.1016/j.nec.2012.04.012

Jian Yang, PhD ^a, Daniel T. Nagasawa, MD ^b, Marko Spasic, BA ^b, Misha Amolis, BS ^b, Winward Choy, BA ^b, Heather M. Garcia, BS ^b, Robert M. Prins, PhD ^b,^c, Linda M. Liau, MD, PhD ^d, Isaac Yang, MD ^b,^c,^⁎

^a Department of Biological Chemistry, David Geffen School of Medicine at University of California, Los Angeles, 310 BSRB, P.O. Box 951737, Los Angeles, CA 90095-1737, USA

^b Department of Neurosurgery Surgery, University of California, Los Angeles, 695 Charles E Young Drive South, Gonda 3357, Los Angeles, CA 90095-1761, USA

^c University of California Los Angeles Jonsson Comprehensive Cancer Center, 8-684 Factor Building, Box 951781, Los Angeles, CA 90095-1781, USA

^d Department of Neurosurgery, UCLA Medical Center, 10833 Le Conte Avenue, CHS 74-145, Los Angeles, CA 90095-6901, USA

^∗ Corresponding author. UCLA Department of Neurosurgery, UCLA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, David Geffen School of Medicine at UCLA, 695 Charles East Young Drive South, UCLA Gonda 3357, Los Angeles, CA 90095-1761 Corresponding author. UCLA Department of Neurosurgery UCLA Jonsson Comprehensive Cancer Center University of California, Los Angeles David Geffen School of Medicine at UCLA 695 Charles East Young Drive South, UCLA Gonda 3357 Los Angeles CA 90095-1761

Résumé

Endogenous vaults are ribonucleoproteins expressed throughout various cell types and across numerous species. Several central nervous system (CNS) tumors have been reported to exhibit high levels of major vault protein (MVP). The vault has been hypothesized to play a role in cellular transport. Although further studies are needed to elucidate the mechanisms of endogenous vault function, these advances may enable the development of targeted therapies to prevent cancer cells from acquiring MVP-related drug resistance. In addition, they seem suited for use as nanocapsules for delivering various therapeutic agents and immunogenic proteins, representing a promising prospect for CNS tumor immunotherapy.

Le texte complet de cet article est disponible en PDF.

Keywords : Brain tumor, Immunotherapy, Nanoparticle, Targeted therapy, Vault

Plan

Introduction

Vault nanoparticles: an overview

MVP: the MVP subunit

vPARP: the vPARP subunit

TEP1: the TEP1 subunit

Untranslated RNA

Vaults and the CNS

Potential uses for future therapies

Summary

Daniel Nagasawa was supported by an American Brain Tumor Association Medical Student Summer Fellowship in Honor of Connie Finc. Isaac Yang (senior author) was partially supported by a Visionary Fund Grant, an Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research UCLA Scholars in Translational Medicine Program Award, the Stein Oppenheimer Endowment Award, and the STOP CANCER Jason Dessel Memorial Seed Grant.

Export

Vol 23 - N° 3

P. 451-458 - juillet 2012 Retour au numéro

Article précédent

Nanotechnology Applications for Glioblastoma
Edjah K. Nduom, Alexandros Bouras, Milota Kaluzova, Costas G. Hadjipanayis

| Article suivant

Clinical Trials with Immunotherapy for High-Grade Glioma
Jacob Ruzevick, Christopher Jackson, Jillian Phallen, Michael Lim

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas : Implications for Future Targeted Therapies - 28/06/12

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL